Limb reduction in an Esco2 cohesinopathy mouse model is mediated by p53-dependent apoptosis and vascular disruption.
Arielle S StrasserAna Silvia Gonzalez-ReicheXianxiao ZhouBraulio Valdebenito-MaturanaXiaoqian YeBin ZhangMeng WuHarm van BakelEthylin Wang JabsPublished in: Nature communications (2024)
Roberts syndrome (RBS) is an autosomal recessive disorder with profound growth deficiency and limb reduction caused by ESCO2 loss-of-function variants. Here, we elucidate the pathogenesis of limb reduction in an Esco2 fl/fl ;Prrx1-Cre Tg/0 mouse model using bulk- and single-cell-RNA-seq and gene co-expression network analyses during embryogenesis. Our results reveal morphological and vascular defects culminating in hemorrhage of mutant limbs at E12.5. Underlying this abnormal developmental progression is a pre-apoptotic, mesenchymal cell population specific to mutant limb buds enriched for p53-related signaling beginning at E9.5. We then characterize these p53-related processes of cell cycle arrest, DNA damage, cell death, and the inflammatory leukotriene signaling pathway in vivo. In utero treatment with pifithrin-α, a p53 inhibitor, rescued the hemorrhage in mutant limbs. Lastly, significant enrichments were identified among genes associated with RBS, thalidomide embryopathy, and other genetic limb reduction disorders, suggesting a common vascular etiology among these conditions.
Keyphrases
- single cell
- cell death
- cell cycle arrest
- rna seq
- mouse model
- pi k akt
- dna damage
- signaling pathway
- copy number
- oxidative stress
- high throughput
- genome wide
- wild type
- poor prognosis
- intellectual disability
- endoplasmic reticulum stress
- bone marrow
- epithelial mesenchymal transition
- case report
- replacement therapy
- duchenne muscular dystrophy
- genome wide identification
- combination therapy